How Vertex Pharmaceuticals Succeeds with Serial Innovation

Learn why culture and constant innovation are essential to developing life-changing biopharma treatments. Vertex Pharmaceuticals focuses on “serial innovation” because this year’s billion-dollar blockbuster drug could become next year’s failure. How does this biopharmaceutical company recruit and onboard employees, and how does it create a culture where the best ideas thrive? Join David Young and guest Reshma Kewalramani, president and CEO at Vertex Pharmaceuticals and a recipient of the 2025 CED Distinguished Leadership Awards. You’ll learn about Kewalramani’s career path, what the company learned from developing a hepatitis C drug, and why the company welcomes in students to experiment alongside employees. The Leadership in Challenging Times discussions feature timely and insightful discussions with the outstanding CEOs who are recipients of CED’s Distinguished Leadership Awards. Business leader honorees discuss the unprecedented challenges facing the nation and how they are helping chart a path forward for both their companies and communities in which they operate. For more from The Conference Board: ·         CED Announces Recipients of Its 2025 Distinguished Leadership Awards ·         CED Distinguished Leadership Awards Celebration ·         Women in STEM: Closing the Gender Gap